Class Effect Unveiled: PPARγ Agonists and MEK Inhibitors in Cancer Cell Differentiation
Cells · 2024
DOI: 10.3390/cells13171506 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2024. Verfasst von Rakefet Ben-Yishay und 10 weiteren Autor:innen. Beteiligte Einrichtung: Oncology Institute, Sheba Medical Center, Ramat Gan 5262000, Israel. Hauptthemen laut MEDLINE: PPAR gamma, Cell Differentiation, Pioglitazone. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Israel Cancer Association.
Abstract (Originalsprache)
Epithelial-to-mesenchymal transition (EMT) plays a major role in breast cancer progression and the development of drug resistance. We have previously demonstrated a trans-differentiation therapeutic approach targeting invasive dedifferentiated cancer cells. Using a combination of PPARγ agonists and MEK inhibitors, we forced the differentiation of disseminating breast cancer cells into post-mitotic adipocytes. Utilizing murine breast cancer cells, we demonstrated a broad class effect of PPARγ agonists and MEK inhibitors in inducing cancer cell trans-differentiation into adipocytes. Both Rosiglitazone and Pioglitazone effectively induced adipogenesis in cancer cells, marked by PPARγ and C/EBPα upregulation, cytoskeleton rearrangement, and lipid droplet accumulation. All tested MEK inhibitors promoted adipogenesis in the presence of TGFβ, with Cobimetinib showing the most prominent effects. A metastasis ex vivo culture from a patient diagnosed with triple-negative breast cancer demonstrated a synergistic upregulation of PPARγ with the combination of Pioglitazone and Cobimetinib. Our results highlight the potential for new therapeutic strategies targeting cancer cell plasticity and the dedifferentiation phenotype in aggressive breast cancer subtypes. Combining differentiation treatments with standard therapeutic approaches may offer a strategy to overcome drug resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Oncology Institute, Sheba Medical Center, Ramat Gan 5262000, Israel.
- Institute of Pathology, Sheba Medical Center, Ramat Gan 5262000, Israel.
- Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.
- Curesponse Ltd., Rehovot 7670102, Israel.
ORCID-Profile: Neta Bar-Hai, Dana Ishay-Ronen
Förderung
- Israel Cancer Association
Zitieren
APA
Ben-Yishay, R., Globus, O., Balint-Lahat, N., Arbili-Yarhi, S., Bar-Hai, N., Bar, V., Aharon, S., Kosenko, A., Zundelevich, A., Berger, R., & Ishay-Ronen, D. (2024). Class Effect Unveiled: PPARγ Agonists and MEK Inhibitors in Cancer Cell Differentiation. Cells. https://doi.org/10.3390/cells13171506
Vancouver
Ben-Yishay R, Globus O, Balint-Lahat N, Arbili-Yarhi S, Bar-Hai N, Bar V, et al. Class Effect Unveiled: PPARγ Agonists and MEK Inhibitors in Cancer Cell Differentiation. Cells. 2024. doi:10.3390/cells13171506
BibTeX
@article{BenYishay2024,
author = {Ben-Yishay, Rakefet and Globus, Opher and Balint-Lahat, Nora and Arbili-Yarhi, Sheli and Bar-Hai, Neta and Bar, Vered and Aharon, Sara and Kosenko, Anna and Zundelevich, Adi and Berger, Raanan and Ishay-Ronen, Dana},
title = {Class Effect Unveiled: PPARγ Agonists and MEK Inhibitors in Cancer Cell Differentiation},
journal = {Cells},
year = {2024},
doi = {10.3390/cells13171506}
}
EUVIMED